pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Sep 17·1 min read
save

FDA hiring drive to add 2,000 staff stalls due to overwhelmed HR center

Sep 17, 2026·read at STAT ↗RegulatoryNeutral

The Food and Drug Administration says it plans to bring on more than 2,000 new employees, a move aimed at rebuilding staff after the 2025 cuts that eliminated about 3,500 positions.

Agency officials, including Karim Mikhail of the Center for Biologics Evaluation and Research, have publicly highlighted the hiring effort at industry conferences and on social media, sharing photos of recent hires.

However, the FDA’s human‑resources office is struggling to process the influx of applications, creating bureaucratic delays that are slowing the recruitment timeline.

The hiring bottleneck underscores the lingering impact of the earlier workforce reductions, even as the agency works to restore its staffing levels.

Industry observers note that a fully staffed FDA is critical for timely drug reviews, making the HR slowdown a concern for pharmaceutical companies and investors alike.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: The FDA’s rebuilding effort is running into a new challenge”

read at STAT ↗
481 words · retrieved Sep 17
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

topics
CardiologyHeart FailureType 2 Diabetes

related stories

  • Oct 16iPSCs come of age, powering breakthroughs in the lab and clinicBioSpace
  • Sep 23STAT+: UnitedHealth, CVS push back on Medicare plan to curb remote patient monitoringSTAT
  • Sep 18Refreshed Novo corrals 3 new early-stage obesity drugs from KallyopeFierce Biotech
  • Sep 16U.S. reaches highest number of measles deaths in decadesSTAT
  • Sep 15STAT+: Medicare to expand its pilot that pays for technology to manage chronic diseasesSTAT